Prospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. May 28, 2024; 15(3): 90757
Published online May 28, 2024. doi: 10.4292/wjgpt.v15.i3.90757
Table 5 Relief of altered stool pattern at weeks 2 and 4 of GASTRAP® DIRECT treatment
Symptom relief (% vs W0)
W2 (%)
W4 (%)
Constipation
    Unchanged5854
    Relief (very much, considerable)42 (27, 15)46 (37, 9)
Diarrhea
    Unchanged4442
    Relief (very much, considerable)46 (42, 14)58 (39, 19)
Defecatory disorders
    Unchanged5658
    Relief (very much, considerable)44 (36, 8)42 (31, 11)

  • Citation: Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World J Gastrointest Pharmacol Ther 2024; 15(3): 90757
  • URL: https://www.wjgnet.com/2150-5349/full/v15/i3/90757.htm
  • DOI: https://dx.doi.org/10.4292/wjgpt.v15.i3.90757